24-24 April 2023
keyboard_arrow_left See all news

Recent News

27 Sep, 2022 /
Nordson Medical
Nordson MEDICAL Opens Tecate Mexico Medical Device Manufacturing Facility
Nordson MEDICAL announces the official opening of its Tecate, Mexico, Medical Device Man...
14 Sep, 2022 /
Qosina Expands Class VI Tubing Portfolio for Single-Use Medical Device and Bioprocess Applications
Qosina expands its Class VI tubing portfolio with several new brands
26 Aug, 2022 /
Smalley Wins GM Supplier Quality Excellence Award for 10th Consecutive Year
Smalley receives the General Motors Supplier Quality Excellence Award for the 10th conse...
26 Jul, 2022 /
Qosina Adds the AseptiQuik STC Series to Its Line of Steam-Thru Connectors
Qosina introduces the AseptiQuik® STC connectors to its line of Steam-Thru® connectors
08 Jul, 2022 /
Smalley Europe Celebrates 20 Years of Local Service
Smalley celebrates 20 years in the European market
HS Design Inc.
/ 18 Dec, 2019
keyboard_arrow_left See all news

HS Design, Inc. Awarded Phase II Contract from the National Institutes of Health

Mr. Michael Quinn, VP of Design & Engineering and Principal Investigator at HSD stated, “The Phase II contract helps solve the chicken and egg problem: develop a device first or wait for the taste-masked multiparticulate formulations. Pharmaceutical companies are hesitant to work on medicinal formulas without a reliable delivery device. The Phase II contract is therefore vital to the continued development of the small form-factor Sympfiny system, also known as Sympfiny 1ml.”

Pediatric cancer drugs are often dosed in very small volumes but also need to be adjusted based on body weight or a child’s size. The 1ml Sympfiny is ideally suited to this task. Sympfiny® is the first multiparticulate delivery device to dose the same as traditional liquid dispensers, creating an intuitive and user-friendly experience. Its proprietary dispensing technology is a revolutionary delivery system that enables a new generation of multiparticulate drug formulations to be delivered with high dose flexibility and with performance, features, and form factors that increase safe and effective administration of drugs.

The breakthrough system enables caregivers to store, extract, and deliver dry drugs with the same familiar technique used with liquid oral drugs. The patent-pending design allows a controlled and precise dosage and ensures all medication is dispensed directly to the child’s mouth. For more information on Sympfiny, please visit: https://sympfiny.com

“We are extremely grateful for the NIH’s continued support of our technology development,” noted Tor Alden, President of HS Design.  The NIH is making it possible for us to contribute in commercializing a truly novel way for dispensing oral pediatric cancer medication. “


ABOUT HS Design: HSD is an award winning, user centered product development firm with a focus in the medical, healthcare, and life science marketplace. For over 40 years, HSD has been recognized for expertise in the areas of design research, strategy, human factors, user experience, industrial design, and mechanical engineering. HSD is a FDA compliant and ISO 13485 certified organization with team members proudly serving on the AAMI Human Factors Committee and assisting with Use and Usability guidance documents (ISO 62366 and IEC 62366). By approaching products from a user-centered perspective, HSD is confident in designing and developing products for a diverse environment. For more information about HSD, please visit: https://hs-design.com

About the SBIR/STTR: The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, also known as America’s Seed Fund, are one of the largest sources of early-stage capital for technology commercialization in the United States. These programs allow US-owned and operated small businesses to engage in federal research and development that has a strong potential for commercialization. The purpose of these programs is to support small businesses with the most innovative, cutting-edge ideas that have the potential to become great commercial successes and make huge societal impacts.

Processing. Please wait.